Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global human insulin market size reached US$ 45.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 68.0 Billion by 2028, exhibiting a growth rate (CAGR) of 6.48% during 2023-2028.

Human insulin (HI) is a short-acting form of insulin used to treat hyperglycemia caused by type 1 and type 2 diabetes. It is produced by recombinant DNA technology and identical to endogenously made insulin. It is used to take the place of insulin generally produced by the body and aids in insulating sugar from the blood into other body tissues, wherein it is utilized for energy. It induces lower titers of circulating insulin antibodies and minimizes skin reactions. At present, manufacturers are introducing an inhalable form intended to be used as a bolus meal-time insulin.

Human Insulin Market Trends:
The increasing prevalence of diabetes on account of sedentary lifestyles, unhealthy dietary patterns, and high-stress levels represents one of the major factors positively influencing the demand for HI around the world. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. In addition, key players are introducing pen devices and safety pen needles to administer HI in the body. It assists in minimizing discomfort and reducing the risks of injuries, infections, and bloodborne pathogen transmission. Apart from this, the growing public awareness about the benefits of using HI and the increasing health consciousness among individuals is driving the market. Besides this, significant improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of biotechnology conducted by leading industry players are creating a positive outlook in the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global human insulin market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, distribution channel and disease type.

Breakup by Product Type:

Drugs
Human Insulin Analogs and Biosimilars
Rapid Acting
Long Acting
Premixed
Human Insulin Biologics
Short Acting
Intermediate Acting
Premixed
Delivery Devices
Pens
Reusable Pens
Disposable Pens
Pen Needles
Standard Pen Needles
Safety Pen Needles
Syringes
Others

Breakup by Distribution Channel:

Retail Pharmacies
Hospital Pharmacies
Online Retail Stores
Others

Breakup by Disease Type:

Type I Diabetes
Type II Diabetes

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being B. Braun Melsungen AG, Becton, Dickinson and Company (BD), Biocon, Eli Lilly and Company, Gulf Pharmaceutical Industries (Julphar), Novo Nordisk A/S, Pfizer Inc., Groupe Sanofi, SEDICO Co., Wockhardt Limited, Ypsomed AG, etc.

Key Questions Answered in This Report:
How has the global human insulin market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global human insulin market?
What are the key regional markets?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the delivery devices?
What is the breakup of the market based on the distribution channel?
What is the breakup of the market based on the disease type?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global human insulin market and who are the key players?
What is the degree of competition in the industry?